Cleven
Generic Name
Enoxaparin Sodium (8000 anti-Xa IU)
Manufacturer
Example Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| cleven 8000 anti xa injection | ৳ 650.00 | N/A |
Description
Overview of the medicine
Cleven 8000 anti-Xa Injection is a low molecular weight heparin (LMWH) used to prevent and treat blood clots. It works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade.
Uses & Indications
Dosage
Adults
Varies by indication. For DVT prophylaxis, typically 40 mg (4000 anti-Xa IU) once daily SC. For DVT treatment, typically 1 mg/kg (100 anti-Xa IU/kg) every 12 hours SC.
Elderly
No dose reduction is generally required unless renal function is impaired.
Renal_impairment
Dosage adjustment is necessary for patients with severe renal impairment (creatinine clearance <30 mL/min). For DVT prophylaxis, 20 mg once daily SC. For DVT treatment, 1 mg/kg once daily SC.
How to Take
Administer by subcutaneous injection into the abdominal wall. Do not inject intramuscularly. Alternate injection sites.
Mechanism of Action
Enoxaparin potentiates the activity of antithrombin III (ATIII), primarily by inhibiting Factor Xa and, to a lesser extent, Factor IIa (thrombin). Inhibition of Factor Xa prevents thrombin generation and, consequently, fibrin formation.
Pharmacokinetics
Onset
Within 3-5 hours post-SC injection.
Excretion
Mainly renal, as intact or desulfated fragments. Approximately 40% of the dose is excreted via urine within 24 hours.
Half life
Approximately 4.5 to 7 hours based on anti-Xa activity after a single SC dose. Longer in patients with renal impairment.
Absorption
Rapid and complete after subcutaneous (SC) administration. Peak plasma anti-Xa activity is achieved within 3 to 5 hours.
Metabolism
Primarily hepatic desulfation and depolymerization into smaller fragments with lower biological activity.
Side Effects
Contraindications
- •Active major bleeding or conditions with high risk of uncontrolled hemorrhage.
- •Hypersensitivity to enoxaparin, heparin, or any excipients.
- •History of heparin-induced thrombocytopenia (HIT) with or without thrombosis.
- •Acute bacterial endocarditis.
Drug Interactions
Other thrombolytic agents
Significantly increased risk of hemorrhage.
NSAIDs (e.g., ibuprofen, naproxen)
Increased risk of bleeding. Use with caution.
Antiplatelet agents (e.g., aspirin, clopidogrel)
Increased risk of bleeding. Use with caution.
Oral anticoagulants (e.g., warfarin, dabigatran)
Increased risk of bleeding. Bridge therapy requires careful monitoring.
Storage
Store below 25°C. Do not freeze. Protect from light.
Overdose
Accidental overdose may lead to hemorrhagic complications. The anticoagulant effects can be largely neutralized by intravenous administration of protamine sulfate. A 1 mg dose of protamine neutralizes about 100 anti-Xa IU of enoxaparin.
Pregnancy & Lactation
Pregnancy Category B. Use in pregnant women should be considered only if clearly needed. Enoxaparin is not excreted into breast milk; however, caution should be exercised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture
Availability
Hospitals, Pharmacies
Approval Status
Approved (e.g., FDA, DGDA)
Patent Status
Generic available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
